United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
Amendment No. 1
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: October 31, 2020
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from: ________________ to _______________
Commission File No. 000-56153
NuGenerex Immuno-Oncology, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 04-3208418 |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) |
10102 USA Today Way, Miramar, Florida 33025
(Address of principal executive office)
Registrant's telephone number: (416) 364-2551
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
☒ YES ☐ No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
☒ YES ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Non-accelerated filer ☐ | Smaller reporting company ☒ |
| Emerging Growth Company ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
☐ YES ☒ NO
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock | None | None |
As of December 15, 2020, the registrant had 400,300,000 shares of common stock, $0.001 par value per share, outstanding.
| 1 |
EXPLANATORY NOTE
This Amendment No.1 to our Quarterly Report on Form 10-Q/A (the “10-Q/A”) amends the Quarterly Report on Form 10-Q for the quarter ended October 31, 2020, as originally filed with the Securities and Exchange Commission on December 15, 2020 (the “Original Form 10-Q”).
The purpose of the 10-Q/A is to correct the disclosure in Item 1 of Part II of the Original Form 10-Q to read “None.” No additional changes, revisions, or updates have been made to the original Form 10-Q in this 10-Q/A. This Amendment No. 1 to the Original Form 10-Q speaks as of the original filing date of the Original Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date.
| 2 |
PART II - OTHER INFORMATION
Item 1. Legal Proceedings.
None.
| 14 |
| 3 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| NUGENEREX IMMUNO-ONCOLOGY, INC. | ||
| (Registrant) | ||
| Date: December 15, 2020 | By: | /s/ Joseph Moscato |
| Joseph Moscato | ||
| President and Chief Executive Officer | ||
| Date: December 15, 2020 | By: | /s/ Mark Corrao |
| Mark Corrao | ||
| Chief Financial Officer | ||
| 4 |
